Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Dec;82(6):1363-8.
doi: 10.1016/j.urology.2013.06.062. Epub 2013 Oct 16.

Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study

Hiram Alberto Gay  1 , Jeff M Michalski, Daniel A Hamstra, John T Wei, Rodney L Dunn, Eric A Klein, Howard M Sandler, Chris Saigal, Mark Litwin, Deborah Kuban, Larry Hembroff, Peter Chang, Martin G Sanda; PROSTQA Consortium
Collaborators, Affiliations
Multicenter Study

Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study

Hiram Alberto Gay et al. Urology. 2013 Dec.

Abstract

Objective: To evaluate the immediate effects of neoadjuvant androgen deprivation therapy (NADT) on health-related quality of life (HRQOL) among patients undergoing radiation therapy (RT) for newly diagnosed prostate cancer.

Methods: The Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium is a prospective multi-institutional study. HRQOL is measured with the Expanded Prostate Cancer Index Composite-26 questionnaire. Differences in patient-reported HRQOL were observed between pretreatment and 2 months after NADT start (and before definitive RT) with significant differences evaluated by paired t test.

Results: From among 450 patients who completed the Expanded Prostate Cancer Index Composite-26 before and 2 months after NADT start, 71 received NADT before proceeding with definitive RT. Patients receiving NADT experienced significant impairment in vitality/hormonal (P <.0001) and sexual (P <.0001) HRQOL after NADT initiation. The mean ± standard deviation vitality/hormonal score fell from an average of 94.1 ± 9.7 before NADT to 78.7 ± 16.3 two months after NADT initiation; and sexual HRQOL fell from a mean of 51.7 ± 31.1 pretreatment to 32.3 ± 26.1 after NADT initiation. Both these HRQOL domain changes exceeded the thresholds for clinical significance. Patients receiving NADT also experienced a significant impairment in urinary continence (P = .024), although this difference did not meet the criteria for clinical significance.

Conclusion: In this analysis, patients receiving NADT experience significant impairment in sexual and vitality/hormonal HRQOL even before starting definitive RT. The significant effect of this therapy on HRQOL needs to be considered before initiating NADT in men where there is no clear evidence of clinical benefit.

PubMed Disclaimer

Comment in

  • Editorial comment.
    Resnick MJ. Resnick MJ. Urology. 2013 Dec;82(6):1368-9. doi: 10.1016/j.urology.2013.06.065. Epub 2013 Oct 16. Urology. 2013. PMID: 24139343 No abstract available.
  • Reply: To PMID 24139340.
    Gay HA. Gay HA. Urology. 2013 Dec;82(6):1369. doi: 10.1016/j.urology.2013.06.066. Epub 2013 Oct 16. Urology. 2013. PMID: 24139355 No abstract available.

References

    1. Montgomery R. Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer (NCT01023061) 2013 [cited 2013 3/19/2013]; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01023061?term=NCT01023061&rank=1.
    1. Michaelson MD. Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer. 2013 [cited 2013 3/19/2013]; Available from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study....
    1. D’Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289–95. - PubMed
    1. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107–18. - PubMed
    1. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–9. - PubMed

Publication types